{"gene":"CCL19","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2000,"finding":"CCL19 (ELC) and CCL21 (SLC) are co-expressed by T zone stromal cells in secondary lymphoid organs; deletion of both ELC and SLC genes occurs in plt/plt mice, which show disrupted T cell and dendritic cell trafficking to lymphoid tissues.","method":"Bone marrow reconstitution, double in situ hybridization, genetic mouse model (plt/plt)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ISH, bone marrow reconstitution, genetic model) in a highly cited foundational paper","pmids":["11070085"],"is_preprint":false},{"year":2001,"finding":"CCL19 is transcytosed from perivascular spaces to the luminal surface of high endothelial venules (HEVs), enabling CCR7-mediated T cell arrest and lymph node homing.","method":"In situ hybridization, immunostaining, footpad injection of CCL19 in mice, T cell trafficking assay in plt/plt mice","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ISH, IHC, in vivo rescue in plt/plt mice) demonstrating transcytosis and functional T cell homing","pmids":["11342595"],"is_preprint":false},{"year":2000,"finding":"MRP1-mediated transport of leukotriene C4 (LTC4) is required for optimal dendritic cell chemotaxis toward CCL19; cysteinyl leukotrienes promote CCL19-dependent DC migration from the epidermis to lymph nodes.","method":"MRP1 knockout mice, exogenous LTC4/LTD4 rescue, in vitro chemotaxis assay, in vivo CCL19 antagonism","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO with rescue, in vitro and in vivo mechanistic dissection in a highly cited Cell paper","pmids":["11114332"],"is_preprint":false},{"year":2001,"finding":"CCL19 induces rapid, concentration-dependent internalization of its receptor CCR7 and receptor desensitization, whereas CCL21 does not internalize CCR7; internalized CCR7 is re-expressed after CCL19 removal.","method":"Flow cytometry, receptor internalization assays, functional re-stimulation assays in T lymphocytes and CCR7-bearing cells","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays (flow cytometry, desensitization, re-expression) with clear mechanistic conclusion, widely cited","pmids":["11745346"],"is_preprint":false},{"year":2008,"finding":"CCR7 internalization following CCL19 (but not CCL21) binding requires arrestin 3 (beta-arrestin 2); siRNA knockdown of arrestin 3 abolishes CCL19-induced CCR7 internalization and blocks migration to CCL19 but not CCL21.","method":"siRNA knockdown of arrestin 2/3 in HuT 78 cells, arrestin 2−/−/arrestin 3−/− MEF reconstitution with GFP-tagged arrestins, immunofluorescence microscopy, migration assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — siRNA KD plus double-KO reconstitution with mutagenesis-equivalent rescue, multiple orthogonal methods","pmids":["18802075"],"is_preprint":false},{"year":2000,"finding":"CCL19 (ELC) binds with high affinity to a novel atypical receptor, CCX-CKR (provisionally CCR10), in addition to CCR7; this receptor also binds CCL21 and CCL25 (TECK) but not most other chemokines.","method":"Stalkokine adhesion assay, radiolabeled ligand binding, competition with >80 chemokines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — direct radioligand binding and competition assay with broad chemokine panel identifying CCL19 as high-affinity CCX-CKR ligand","pmids":["10706668"],"is_preprint":false},{"year":2006,"finding":"CCX-CKR (ACKR4) mediates efficient scavenging of CCL19 by internalizing and degrading it; unlike CCR7, CCX-CKR does not become refractory and progressively degrades large quantities of CCL19. CCX-CKR internalization is independent of beta-arrestins and clathrin-coated pits but is blocked by caveolin-1 overexpression.","method":"Transfected HEK293 cells, CCL19 internalization and degradation assays, siRNA, caveolin-1 overexpression","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple mechanistic assays (internalization, degradation, pathway inhibitors) in reconstituted cell system","pmids":["16791897"],"is_preprint":false},{"year":2003,"finding":"CCL19/CCL21-triggered migration of dendritic cells requires prostaglandin E2 (PGE2); PGE2 enables CCR7 coupling to PI3K-mediated phosphorylation of Akt and intracellular calcium mobilization. DC migration to CCL19/CCL21 depends on phospholipase C and calcium flux but not on PI3K.","method":"Human monocyte-derived DC cultures, PI3K inhibitors, calcium mobilization assays, migration assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple signaling pathway dissection with pharmacological inhibitors and functional migration readouts","pmids":["14592837"],"is_preprint":false},{"year":2015,"finding":"CCL19 solution structure contains a canonical chemokine fold; the N-termini of PSGL-1 and CCR7 have overlapping, competitively binding sites on CCL19, suggesting a mechanism by which PSGL-1 co-receptor expression enhances CCL19-driven T cell recruitment.","method":"NMR solution structure determination, chemical shift mapping","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with chemical shift mapping providing direct structural evidence for receptor binding sites","pmids":["26115234"],"is_preprint":false},{"year":2009,"finding":"CCL19 is a specific ligand for the atypical receptor CRAM (CCRL2/CRAM-B); CRAM binds CCL19 with affinity similar to CCR7 but does not trigger calcium mobilization or chemotaxis; instead CRAM constitutively recycles via clathrin-coated pits and internalizes CCL19.","method":"Radioactive ligand binding, calcium mobilization assay, migration assay, constitutive recycling assay, anti-CRAM antibody internalization","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct radioligand binding and functional assays in single lab identifying CRAM as atypical CCL19 receptor","pmids":["20002784"],"is_preprint":false},{"year":2016,"finding":"ACKR4 on keratinocytes and dermal lymphatic endothelial cells scavenges dermal CCL19 during cutaneous inflammation; loss of ACKR4 impairs Langerhans cell egress and dermal DC accumulation in lymph nodes, and this defect is fully rescued by genetic deletion of CCL19.","method":"Ackr4-deficient mice, Ccl19/Ackr4 double-deficient mice, flow cytometry of skin and draining LN APCs","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double-KO rescue definitively placing ACKR4 upstream of CCL19 in APC egress pathway","pmids":["26976955"],"is_preprint":false},{"year":2010,"finding":"CCL21 alone is sufficient for DC migration from skin, DC maturation, and efficient T cell priming in vivo; CCL19-deficient mice with intact CCL21 expression show normal DC homeostasis and function, demonstrating CCL19 is redundant for these processes.","method":"CCL19-deficient mice with varying CCL21 levels, flow cytometry of DC localization and frequency, T cell priming assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with functional immune readouts demonstrating dispensability of CCL19 for DC migration in vivo","pmids":["20201039"],"is_preprint":false},{"year":2011,"finding":"In a 3D microfluidic system, DCs can sense CCR7 ligand gradients as small as 0.4%; CCL19 and CCL21 show similar sensitivity at small gradients but CCL21 is a more potent directional cue at higher gradients, even when matrix-binding of CCL21 is prevented, suggesting differential receptor signaling rather than matrix binding underlies the difference.","method":"Microfluidic 3D gradient device, DC chemotaxis assay in collagen matrices, neutralization of matrix binding","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — quantitative reconstituted 3D system with controlled gradients, multiple conditions tested","pmids":["21422278"],"is_preprint":false},{"year":2007,"finding":"CCL19 (and CCL21) treatment of resting CD4+ T cells increases HIV-1 permissiveness without inducing T cell activation or proliferation, resulting in high levels of integrated HIV-1 DNA and post-integration latency upon restimulation.","method":"HIV-1 infection of purified resting CD4+ T cells pre-treated with CCL19/CCL21, integrated HIV DNA quantification, reactivation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic in vitro experiment with integration quantification and latency reactivation, highly cited","pmids":["17881634"],"is_preprint":false},{"year":2016,"finding":"HIV integration in CCL19-treated resting CD4+ T cells requires NF-κB signaling; CCL19 induces phosphorylation of Akt, NF-κB, ERK, and p38, and CCL19 treatment stabilizes HIV integrase by promoting its interaction with Pin1 (reduced by JNK inhibition). HIV mutants lacking NF-κB binding sites in the LTR show 40-fold reduced integration in CCL19-treated cells versus only 5-fold reduction in activated T cells.","method":"Pathway inhibitors (PI3K, MEK, JNK, AP-1, NF-κB inhibitors), NF-κB-mutant HIV infection, Alu-LTR and 2-LTR qPCR, co-immunoprecipitation of integrase with Pin1, integration site analysis","journal":"Retrovirology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple pharmacological pathway dissection, mutant virus, and molecular co-IP defining NF-κB requirement","pmids":["27459960"],"is_preprint":false},{"year":2012,"finding":"CCR7/CCL19 signaling in T cells upregulates ERK5 expression and phosphorylation, leading to subsequent induction of KLF-2 and EDG-1 (S1P1), thereby linking CCL19-mediated lymph node entry to S1P1-dependent lymph node egress.","method":"CCL19 stimulation of HuT78 and primary murine T cells, Western blot for ERK5/KLF-2/EDG-1, ERK5 conditional KO (ERK5flox/flox/Lck-Cre), migration assay to S1P","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic KO with migration readout plus time-course signaling pathway analysis","pmids":["22334704"],"is_preprint":false},{"year":2023,"finding":"CCR7 functions both as a sensor (directional receptor) and as a sink (ligand consumer) for CCL19 in dendritic cells; CCR7 internalization after CCL19 binding creates a local chemokine gradient, enabling self-organized collective DC migration and long-range guidance.","method":"Live-cell imaging of DC chemotaxis, computational modeling, receptor internalization quantification, gradient visualization","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 — experimental data combined with theory, multiple orthogonal methods demonstrating dual sensory/sink role","pmids":["37656776"],"is_preprint":false},{"year":2006,"finding":"A CCL19 N-terminal truncation mutant CCL19(8-83) specifically antagonizes CCL19-induced chemotaxis and calcium mobilization without affecting CCL21 responses; treatment of mice with this antagonist inhibits cytotoxic T lymphocyte generation against allogeneic dendritic cells, demonstrating a specific role for CCL19 in immune priming.","method":"In vitro chemotaxis and calcium mobilization assays, in vivo CCL19 antagonist treatment, allogeneic CTL generation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — specific antagonist mutagenesis with in vitro and in vivo functional validation","pmids":["15231820"],"is_preprint":false},{"year":2006,"finding":"CCL19/CCL21 promote activation-induced cell death (AICD) of antigen-responding CD4+ T cells during the clonal contraction phase, partially through enhancing Fas ligand expression; plt/plt mice lacking CCL19/CCL21 show prolonged T cell expansion and impaired AICD.","method":"OVA/CFA immunization of plt/plt and wild-type mice, in vivo tracking of OVA-responding T cells, in vitro AICD assay with anti-CD3/CD28, Fas ligand expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic model combined with in vitro mechanistic assays and Fas ligand pathway identification","pmids":["16973962"],"is_preprint":false},{"year":2013,"finding":"CCL19/CCR7 signaling in A549 lung cancer cells upregulates heparanase expression via transcription factor Sp1; Sp1 binds to the heparanase gene promoter (ChIP assay), and this pathway promotes tumor cell invasion.","method":"Recombinant CCL19 stimulation, CCR7 blockade, Sp1 siRNA, chromatin immunoprecipitation (ChIP), qPCR/Western blot, Transwell invasion assay","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP validation of Sp1-heparanase promoter binding plus functional invasion assay, single lab","pmids":["23649655"],"is_preprint":false},{"year":2009,"finding":"PGE2 induces CCR7 expression on human monocytes and enables migration to CCL19 and CCL21 via EP2/EP4 receptor engagement, cAMP elevation, and the cAMP/PKA pathway; p38 MAPK is required for CCR7 mRNA transcription; transcription factors CREB-1, C/EBPα, and C/EBPβ translocate to the nucleus and bind the CCR7 promoter following PGE2 stimulation.","method":"PGE2 stimulation of human monocytes, cAMP measurement, PKA/p38/MAPK pathway inhibitors, transcription factor nuclear translocation and promoter binding assays, migration assay","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling pathway inhibitors with transcription factor binding assays, single lab","pmids":["19545899"],"is_preprint":false},{"year":2010,"finding":"PGE2-matured DCs have high surface CCR7 but suppressed CCL19 production; this suppression reduces their ability to attract naive T cells. TLR ligand/IFN-matured DCs produce high CCL19 but have lower surface CCR7 due to auto-internalization in the CCL19-rich maturation environment.","method":"DC maturation protocols, CCL19 ELISA, CCR7 surface staining, in vitro migration assay for naive T cells, in vivo DC tracking with 111In-labeled DCs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo (patient) data with multiple orthogonal methods revealing CCL19 autocrine regulation of CCR7 surface expression","pmids":["20498301"],"is_preprint":false},{"year":2018,"finding":"CCL19 inhibits colorectal cancer angiogenesis through a CCR7-dependent mechanism involving upregulation of miR-206, which suppresses the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway.","method":"Stable CCL19 overexpression/shRNA lentiviral transduction, HUVEC CCR7 shRNA knockdown, HUVEC proliferation/migration/sprouting assays, in vivo angiogenesis mouse model, pathway Western blot","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with CCR7 shRNA and in vivo model, pathway mechanistically defined, single lab","pmids":["30250188"],"is_preprint":false},{"year":2015,"finding":"CCL19/CCR7 signaling in ovarian cancer cells promotes epithelial-to-mesenchymal transition (EMT) via ERK signaling, mediated through the adapter protein CrkL; CrkL knockdown suppresses CCL19-stimulated p-ERK and EMT markers (N-cadherin, Snail, MMP9) and reduces invasion, without affecting p-AKT.","method":"CrkL siRNA knockdown in SKOV-3 cells, Western blot for signaling molecules and EMT markers, Transwell invasion and wound healing assays","journal":"Medical oncology","confidence":"Medium","confidence_rationale":"Tier 2 — KD with pathway-specific rescue readouts, single lab","pmids":["25636509"],"is_preprint":false},{"year":2017,"finding":"CCL19/CCR7 interaction in endometrial stromal cells activates PI3K/Akt signaling and upregulates Bcl2, MMP2, and MMP9, thereby promoting ESC proliferation and invasion contributing to endometriosis pathogenesis.","method":"ELISA of peritoneal fluid, cell proliferation and Transwell invasion assays, Western blot for p-AKT/Bcl2/MMP2/MMP9","journal":"American journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 3 — single lab with functional assays and pathway Western blot, moderate mechanistic depth","pmids":["28856757"],"is_preprint":false},{"year":2014,"finding":"CCL19/CCR7 interaction in bone marrow stromal cells (BMSCs) upregulates MMP9 via PI3K/Akt pathway, promoting BMSC migration; LY294002 (PI3K inhibitor) abolishes CCL19-induced Akt phosphorylation and MMP9 upregulation.","method":"Transwell migration assay, Western blot, real-time PCR, LY294002 pharmacological inhibition","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological inhibition with functional migration readout, single lab","pmids":["25086360"],"is_preprint":false},{"year":2011,"finding":"Seminal fluid induces expression of CCL19 in uterine glandular and luminal epithelial cells, and CCL19 acts through CCR7 to recruit FOXP3+ regulatory T cells to the uterus prior to embryo implantation; both seminal plasma and sperm are required for maximal CCL19 expression.","method":"Flow cytometry, immunohistochemistry, qPCR, mating with seminal vesicle-deficient males","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function (seminal vesicle KO) with multiple readouts establishing CCL19 as mediator of uterine Treg recruitment","pmids":["21389340"],"is_preprint":false},{"year":2019,"finding":"CCL19-expressing astrocytes are required for gliosis-induced CNS lymphoma development; CCL19 from astrocytes retains CCR7+ lymphoma cells in brain parenchyma, and deletion of CCL19 in mice or CCR7 from lymphoma cells abrogates CNS lymphoma formation.","method":"CCL19-deleted mice, CCR7-deleted lymphoma cells, two-photon microscopy, xenograft models","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion of both ligand and receptor with in vivo two-photon imaging, multiple orthogonal approaches","pmids":["31526758"],"is_preprint":false},{"year":2024,"finding":"CCL19-secreting fibroblasts facilitate lymphocyte trafficking to tertiary lymphoid structures (TLSs) in colorectal cancer liver metastasis; CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice.","method":"Single-cell RNA-seq, spatial transcriptomics (Stereo-seq), in vitro monoclonal antibody generation from TLS plasma cells, in vivo CCL19 treatment in humanized mouse model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiomics plus in vivo functional experiments demonstrating CCL19+ fibroblast role in TLS formation","pmids":["39137726"],"is_preprint":false},{"year":2001,"finding":"Neutrophils produce biologically active CCL20 and CCL19 (MIP-3β) upon LPS or TNF-α stimulation; neutrophil supernatants induce chemotaxis of immature and mature DCs and trigger CCR7-expressing lymphocyte adhesion to ICAM-1, effects abolished by anti-CCL19 neutralizing antibodies.","method":"LPS/TNF-α stimulation of neutrophils, chemotaxis assay, integrin-dependent adhesion assay, neutralizing antibodies","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional neutralization confirms CCL19 bioactivity in neutrophil supernatants, single lab","pmids":["11449350"],"is_preprint":false},{"year":1998,"finding":"CCL19 (ELC) is a high-affinity ligand for CCR7 on lymphocytes; CCL19 induces calcium mobilization and chemotaxis of CD4+, CD8+ T cells, and B cells but not NK cells, monocytes, or neutrophils; CCR7 mRNA is dramatically upregulated in T cells upon IL-2 or PHA+IL-2 stimulation; CCL19 and CCR7 co-localize in parafollicular regions of lymph nodes by ISH.","method":"ELC-SEAP fusion protein binding assay, calcium mobilization, chemotaxis assay, RT-PCR, in situ hybridization","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1–2 — ligand binding, calcium flux, chemotaxis, and ISH establishing CCL19-CCR7 axis in lymphocyte trafficking; foundational study","pmids":["9701028"],"is_preprint":false},{"year":2023,"finding":"CCL19 promotes TH2 cell differentiation in allergic airway disease; recombinant CCL19 increases STAT5 phosphorylation and upregulates TH2- and IL-2-associated genes in naive CD4+ T cells; Ccl19-deficient mice show reduced allergic inflammation, less IL-4/IL-13 production, and attenuated airway hyperresponsiveness.","method":"Ccl19-deficient mice in OVA asthma model, co-culture of naive CD4+ T cells with Ccl19-deficient DCs or FRCs, recombinant CCL19 stimulation, STAT5 phosphorylation by flow cytometry, RNA-seq","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple in vitro and in vivo readouts plus signaling pathway identification","pmids":["37956733"],"is_preprint":false}],"current_model":"CCL19 is a homeostatic CC chemokine that signals exclusively through CCR7 (and is scavenged by atypical receptors ACKR4/CCX-CKR and CRAM/CCRL2) to drive directed migration of T cells, dendritic cells, and other CCR7+ leukocytes into secondary lymphoid organs; upon CCR7 binding, CCL19 activates Gαi-coupled signaling (calcium flux, PI3K/Akt, ERK, NF-κB) and uniquely triggers arrestin 3-dependent CCR7 internalization and desensitization—unlike CCL21—thereby enabling DCs to act as both sensors and sinks to self-generate chemotactic gradients for collective migration; downstream CCR7/CCL19 signaling also induces ERK5→KLF-2→EDG-1 expression to couple lymph node entry with subsequent egress, promotes T cell AICD via Fas ligand upregulation, facilitates HIV integration in resting CD4+ T cells via NF-κB, drives TH2 differentiation through STAT5 phosphorylation, and in tumor contexts promotes or restrains cancer progression through modulation of immune cell trafficking, tertiary lymphoid structure formation, and angiogenesis suppression via the miR-206/Met/VEGF-A axis."},"narrative":{"teleology":[{"year":1998,"claim":"Identification of CCL19 as a high-affinity CCR7 ligand that selectively chemoattracts T and B cells established the molecular basis of lymphocyte guidance to lymph node parafollicular zones.","evidence":"Ligand binding assay, calcium mobilization, chemotaxis, ISH in human lymphoid tissues","pmids":["9701028"],"confidence":"High","gaps":["CCL19 vs CCL21 functional divergence at CCR7 not yet dissected","in vivo requirement for CCL19 in lymph node homing not tested"]},{"year":2000,"claim":"Co-deletion of CCL19 and CCL21 in plt/plt mice disrupted T cell and DC trafficking to lymphoid organs, proving that CCR7 ligands are non-redundant with other chemokines for lymphoid organogenesis, while identification of CCX-CKR (ACKR4) as a second CCL19-binding receptor revealed a scavenging axis distinct from CCR7.","evidence":"plt/plt genetic model with bone marrow reconstitution and ISH; radioligand binding and competition panel for CCX-CKR","pmids":["11070085","10706668"],"confidence":"High","gaps":["Individual contributions of CCL19 vs CCL21 unresolved in plt/plt model","ACKR4 scavenging mechanism and biological role in vivo unknown"]},{"year":2001,"claim":"Demonstration that CCL19 is transcytosed across HEVs to mediate T cell arrest, and that CCL19 uniquely induces CCR7 internalization and desensitization unlike CCL21, revealed two mechanisms—luminal presentation and biased receptor regulation—by which CCL19 controls lymphocyte entry.","evidence":"Footpad injection with plt/plt rescue; flow cytometry internalization and re-expression assays in T cells","pmids":["11342595","11745346"],"confidence":"High","gaps":["Molecular basis of differential CCR7 internalization by CCL19 vs CCL21 unknown","transcytosis receptor/pathway not identified"]},{"year":2003,"claim":"Mapping of CCL19-triggered DC signaling to PGE2-dependent PI3K/Akt activation and calcium flux defined the intracellular requirements for chemotaxis, with PLC and calcium being essential while PI3K was dispensable for migration per se.","evidence":"Pharmacological pathway dissection in human monocyte-derived DCs with migration and calcium readouts","pmids":["14592837"],"confidence":"High","gaps":["Relative contributions of parallel signaling arms to directional sensing vs speed not resolved","role of Rho GTPases not addressed"]},{"year":2006,"claim":"Three discoveries converged to define CCL19's broader biological actions beyond migration: ACKR4 was shown to constitutively scavenge and degrade CCL19 via a beta-arrestin-independent caveolar pathway; CCL19/CCL21 were found to promote T cell AICD via Fas ligand upregulation; and an N-terminal truncation antagonist (CCL19(8-83)) specifically blocked CCL19 signaling in vivo, enabling dissection of CCL19 vs CCL21 roles in immune priming.","evidence":"HEK293 internalization/degradation assays with siRNA; plt/plt OVA immunization with AICD readout; specific antagonist in allogeneic CTL assay","pmids":["16791897","16973962","15231820"],"confidence":"High","gaps":["In vivo gradient-shaping role of ACKR4 scavenging not demonstrated","AICD mechanism beyond Fas ligand not explored","antagonist selectivity in complex immune responses not fully tested"]},{"year":2008,"claim":"Arrestin 3 was identified as the specific mediator of CCL19-induced CCR7 internalization and migration, resolving why CCL19 and CCL21 produce divergent receptor fates despite sharing CCR7.","evidence":"siRNA knockdown and arrestin double-KO MEF reconstitution with GFP-tagged arrestins, migration assays","pmids":["18802075"],"confidence":"High","gaps":["Downstream signaling events from arrestin 3-CCR7 complexes not characterized","phosphorylation code on CCR7 C-terminus not mapped"]},{"year":2010,"claim":"CCL19-deficient mice with intact CCL21 showed normal DC migration and T cell priming, establishing that CCL19 is dispensable for constitutive DC homeostasis and revealing functional redundancy within the CCR7 ligand pair for steady-state trafficking.","evidence":"CCL19-KO mice with flow cytometry of DC localization and T cell priming assays","pmids":["20201039"],"confidence":"High","gaps":["Non-redundant roles of CCL19 in inflammation or specific immune contexts not yet identified","whether CCL19 is required for fine-tuning gradient shape in vivo unclear"]},{"year":2012,"claim":"CCL19/CCR7 signaling was found to activate ERK5→KLF-2→S1P1 in T cells, coupling CCL19-driven lymph node entry to subsequent S1P1-dependent egress—an unexpected feedback linking chemokine and sphingolipid receptor pathways.","evidence":"CCL19 stimulation of T cells, ERK5 conditional KO (ERK5flox/flox/Lck-Cre), S1P migration assay","pmids":["22334704"],"confidence":"High","gaps":["Whether CCL21 induces the same ERK5-KLF2-S1P1 cascade not tested","in vivo egress kinetics in CCL19-only vs CCL21-only settings unknown"]},{"year":2015,"claim":"NMR solution structure of CCL19 revealed overlapping binding sites for CCR7 and PSGL-1 N-termini, providing a structural basis for co-receptor enhancement of CCL19-driven T cell recruitment.","evidence":"NMR structure determination with chemical shift perturbation mapping","pmids":["26115234"],"confidence":"High","gaps":["No ternary complex structure of CCL19-CCR7-PSGL-1 available","functional validation of competitive binding in cell-based assays not shown"]},{"year":2016,"claim":"Genetic epistasis showed ACKR4 scavenging of CCL19 in skin is required for DC egress to lymph nodes—Ackr4 loss impairs Langerhans cell migration, fully rescued by CCL19 deletion—while CCL19 was shown to facilitate HIV-1 integration in resting CD4+ T cells through NF-κB-dependent integrase stabilization.","evidence":"Ackr4/Ccl19 double-KO mice with DC tracking; NF-κB-mutant HIV, pathway inhibitors, co-IP of integrase with Pin1","pmids":["26976955","27459960"],"confidence":"High","gaps":["Whether ACKR4-CCL19 axis operates similarly in mucosal tissues unknown","HIV integration mechanism confirmed only in vitro","Pin1-integrase interaction specificity to CCL19 context not verified"]},{"year":2019,"claim":"CCL19 produced by reactive astrocytes was shown to retain CCR7+ lymphoma cells in brain parenchyma, establishing a non-immune stromal source of CCL19 as critical for CNS lymphoma pathogenesis.","evidence":"CCL19-deleted mice and CCR7-deleted lymphoma cells with two-photon microscopy and xenograft models","pmids":["31526758"],"confidence":"High","gaps":["Whether this mechanism applies to other brain-tropic malignancies unknown","astrocyte signals inducing CCL19 not identified"]},{"year":2023,"claim":"Two parallel advances redefined CCL19's roles: CCR7 was shown to function as both sensor and sink for CCL19, with ligand consumption enabling self-generated gradients for collective DC migration; separately, CCL19 was found to promote TH2 differentiation via STAT5 phosphorylation, with Ccl19-KO mice showing attenuated allergic airway disease.","evidence":"Live-cell DC imaging with computational modeling; Ccl19-KO in OVA asthma model with STAT5 flow cytometry and RNA-seq","pmids":["37656776","37956733"],"confidence":"High","gaps":["Physical basis of CCR7 ligand consumption kinetics not resolved at structural level","whether STAT5 activation is direct or mediated via IL-2 autocrine loop unclear"]},{"year":2024,"claim":"CCL19-secreting fibroblasts were identified as organizers of tertiary lymphoid structures in colorectal cancer liver metastasis, with exogenous CCL19 promoting TLS neogenesis and anti-tumor immunity in vivo.","evidence":"Single-cell RNA-seq, spatial transcriptomics, humanized mouse model with CCL19 treatment","pmids":["39137726"],"confidence":"High","gaps":["Molecular signals initiating CCL19 expression in tumor fibroblasts not defined","whether CCL19 alone is sufficient or acts with CCL21 for TLS maturation unclear"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of differential arrestin recruitment by CCL19 vs CCL21 at CCR7, the phosphorylation barcode on CCR7 that distinguishes the two ligands, whether CCL19's STAT5-mediated TH2-polarizing function operates independently of its chemotactic role, and how CCL19 production is transcriptionally regulated in non-immune stromal cells such as astrocytes and fibroblasts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No CCR7 phosphosite-resolved structure with CCL19 vs CCL21","STAT5 activation mechanism (direct vs indirect) unresolved","transcriptional regulation of CCL19 in stromal cells poorly characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[30,3,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[30,7,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,28,29]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,11,17,18,31]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,14,15,22,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,14,27]}],"complexes":[],"partners":["CCR7","ACKR4","CCRL2","ARRB2","PSGL1"],"other_free_text":[]},"mechanistic_narrative":"CCL19 is a homeostatic CC chemokine that directs lymphocyte and dendritic cell trafficking to secondary lymphoid organs by signaling through its primary receptor CCR7. CCL19 binds CCR7 to induce calcium mobilization, PI3K/Akt, ERK, and NF-κB signaling, and uniquely triggers arrestin 3-dependent CCR7 internalization and desensitization—unlike its co-ligand CCL21—enabling DCs to act as both gradient sensors and chemokine sinks for self-organized collective migration [PMID:9701028, PMID:18802075, PMID:37656776]. Atypical receptors ACKR4 and CCRL2 scavenge CCL19 without canonical signaling, shaping tissue chemokine gradients critical for dendritic cell egress and immune homeostasis [PMID:16791897, PMID:26976955]. Beyond lymphoid trafficking, CCL19/CCR7 signaling couples lymph node entry to S1P1-dependent egress via ERK5/KLF-2, promotes T cell activation-induced cell death through Fas ligand upregulation, drives TH2 differentiation via STAT5 phosphorylation, facilitates HIV-1 integration in resting CD4+ T cells through NF-κB, and orchestrates tertiary lymphoid structure formation in tumors [PMID:22334704, PMID:16973962, PMID:37956733, PMID:27459960, PMID:39137726]."},"prefetch_data":{"uniprot":{"accession":"Q99731","full_name":"C-C motif chemokine 19","aliases":["Beta-chemokine exodus-3","CK beta-11","Epstein-Barr virus-induced molecule 1 ligand chemokine","EBI1 ligand chemokine","ELC","Macrophage inflammatory protein 3 beta","MIP-3-beta","Small-inducible cytokine A19"],"length_aa":98,"mass_kda":11.0,"function":"May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q99731/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL19","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL19","total_profiled":1310},"omim":[{"mim_id":"608379","title":"CHEMOKINE, CC MOTIF, RECEPTOR-LIKE PROTEIN 2; CCRL2","url":"https://www.omim.org/entry/608379"},{"mim_id":"607003","title":"THYMIC STROMAL LYMPHOPOIETIN; TSLP","url":"https://www.omim.org/entry/607003"},{"mim_id":"606065","title":"ATYPICAL CHEMOKINE RECEPTOR 4; ACKR4","url":"https://www.omim.org/entry/606065"},{"mim_id":"605149","title":"CHEMOKINE, CXC MOTIF, LIGAND 13; CXCL13","url":"https://www.omim.org/entry/605149"},{"mim_id":"603030","title":"TOLL-LIKE RECEPTOR 4; TLR4","url":"https://www.omim.org/entry/603030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":591.4}],"url":"https://www.proteinatlas.org/search/CCL19"},"hgnc":{"alias_symbol":["ELC","MIP-3b","exodus-3","CKb11"],"prev_symbol":["SCYA19"]},"alphafold":{"accession":"Q99731","domains":[{"cath_id":"2.40.50.40","chopping":"28-98","consensus_level":"medium","plddt":93.3169,"start":28,"end":98}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99731","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99731-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99731-F1-predicted_aligned_error_v6.png","plddt_mean":83.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL19","jax_strain_url":"https://www.jax.org/strain/search?query=CCL19"},"sequence":{"accession":"Q99731","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99731.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99731/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99731"}},"corpus_meta":[{"pmid":"29505028","id":"PMC_29505028","title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.","date":"2018","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29505028","citation_count":634,"is_preprint":false},{"pmid":"11070085","id":"PMC_11070085","title":"Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11070085","citation_count":457,"is_preprint":false},{"pmid":"11114332","id":"PMC_11114332","title":"The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11114332","citation_count":353,"is_preprint":false},{"pmid":"11342595","id":"PMC_11342595","title":"The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11342595","citation_count":275,"is_preprint":false},{"pmid":"34325726","id":"PMC_34325726","title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34325726","citation_count":245,"is_preprint":false},{"pmid":"23587803","id":"PMC_23587803","title":"A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system.","date":"2013","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23587803","citation_count":237,"is_preprint":false},{"pmid":"17881634","id":"PMC_17881634","title":"CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17881634","citation_count":200,"is_preprint":false},{"pmid":"14592837","id":"PMC_14592837","title":"CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14592837","citation_count":193,"is_preprint":false},{"pmid":"21389340","id":"PMC_21389340","title":"Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment.","date":"2011","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/21389340","citation_count":179,"is_preprint":false},{"pmid":"21422278","id":"PMC_21422278","title":"Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21422278","citation_count":164,"is_preprint":false},{"pmid":"12209625","id":"PMC_12209625","title":"Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12209625","citation_count":155,"is_preprint":false},{"pmid":"26729814","id":"PMC_26729814","title":"Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26729814","citation_count":155,"is_preprint":false},{"pmid":"31632965","id":"PMC_31632965","title":"CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31632965","citation_count":154,"is_preprint":false},{"pmid":"10706668","id":"PMC_10706668","title":"Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706668","citation_count":154,"is_preprint":false},{"pmid":"11449350","id":"PMC_11449350","title":"Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11449350","citation_count":136,"is_preprint":false},{"pmid":"21225692","id":"PMC_21225692","title":"Characterization of CCL19 and CCL21 in rheumatoid arthritis.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21225692","citation_count":124,"is_preprint":false},{"pmid":"16791897","id":"PMC_16791897","title":"The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16791897","citation_count":123,"is_preprint":false},{"pmid":"12580544","id":"PMC_12580544","title":"Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation.","date":"2003","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/12580544","citation_count":123,"is_preprint":false},{"pmid":"30250188","id":"PMC_30250188","title":"CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30250188","citation_count":122,"is_preprint":false},{"pmid":"17825430","id":"PMC_17825430","title":"CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions.","date":"2007","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17825430","citation_count":109,"is_preprint":false},{"pmid":"39137726","id":"PMC_39137726","title":"CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/39137726","citation_count":108,"is_preprint":false},{"pmid":"11745346","id":"PMC_11745346","title":"The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11745346","citation_count":105,"is_preprint":false},{"pmid":"20498301","id":"PMC_20498301","title":"PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20498301","citation_count":102,"is_preprint":false},{"pmid":"10754294","id":"PMC_10754294","title":"The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10754294","citation_count":102,"is_preprint":false},{"pmid":"10027395","id":"PMC_10027395","title":"Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10027395","citation_count":93,"is_preprint":false},{"pmid":"9701028","id":"PMC_9701028","title":"EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9701028","citation_count":85,"is_preprint":false},{"pmid":"20201039","id":"PMC_20201039","title":"CCL21 is sufficient to mediate DC migration, maturation and function in the absence of CCL19.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20201039","citation_count":78,"is_preprint":false},{"pmid":"18802075","id":"PMC_18802075","title":"Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802075","citation_count":76,"is_preprint":false},{"pmid":"33767695","id":"PMC_33767695","title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33767695","citation_count":73,"is_preprint":false},{"pmid":"29391257","id":"PMC_29391257","title":"CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29391257","citation_count":72,"is_preprint":false},{"pmid":"10222066","id":"PMC_10222066","title":"CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors.","date":"1999","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10222066","citation_count":72,"is_preprint":false},{"pmid":"14662845","id":"PMC_14662845","title":"EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14662845","citation_count":70,"is_preprint":false},{"pmid":"26976955","id":"PMC_26976955","title":"ACKR4 on Stromal Cells Scavenges CCL19 To Enable CCR7-Dependent Trafficking of APCs from Inflamed Skin to Lymph Nodes.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26976955","citation_count":60,"is_preprint":false},{"pmid":"28017968","id":"PMC_28017968","title":"Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28017968","citation_count":58,"is_preprint":false},{"pmid":"16622017","id":"PMC_16622017","title":"Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16622017","citation_count":57,"is_preprint":false},{"pmid":"23873879","id":"PMC_23873879","title":"Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.","date":"2013","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23873879","citation_count":55,"is_preprint":false},{"pmid":"14871974","id":"PMC_14871974","title":"CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/14871974","citation_count":54,"is_preprint":false},{"pmid":"20002784","id":"PMC_20002784","title":"CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.","date":"2009","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20002784","citation_count":54,"is_preprint":false},{"pmid":"27666000","id":"PMC_27666000","title":"Baicalin attenuates inflammation in mice with OVA-induced asthma by inhibiting NF-κB and suppressing CCR7/CCL19/CCL21.","date":"2016","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27666000","citation_count":52,"is_preprint":false},{"pmid":"23731727","id":"PMC_23731727","title":"Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23731727","citation_count":52,"is_preprint":false},{"pmid":"33559069","id":"PMC_33559069","title":"Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/33559069","citation_count":51,"is_preprint":false},{"pmid":"30834316","id":"PMC_30834316","title":"Powerful Anticolon Tumor Effect of Targeted Gene Immunotherapy Using Folate-Modified Nanoparticle Delivery of CCL19 To Activate the Immune System.","date":"2019","source":"ACS central science","url":"https://pubmed.ncbi.nlm.nih.gov/30834316","citation_count":51,"is_preprint":false},{"pmid":"12474232","id":"PMC_12474232","title":"Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin.","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12474232","citation_count":48,"is_preprint":false},{"pmid":"37853185","id":"PMC_37853185","title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.","date":"2023","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37853185","citation_count":47,"is_preprint":false},{"pmid":"18757429","id":"PMC_18757429","title":"CXCL13 is highly produced by Sézary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18757429","citation_count":47,"is_preprint":false},{"pmid":"35020885","id":"PMC_35020885","title":"Does CCL19 act as a double-edged sword in cancer development?","date":"2022","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35020885","citation_count":47,"is_preprint":false},{"pmid":"36479116","id":"PMC_36479116","title":"Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36479116","citation_count":46,"is_preprint":false},{"pmid":"19545899","id":"PMC_19545899","title":"CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19545899","citation_count":46,"is_preprint":false},{"pmid":"30940644","id":"PMC_30940644","title":"Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30940644","citation_count":43,"is_preprint":false},{"pmid":"17947663","id":"PMC_17947663","title":"Regulatory role of lymphoid chemokine CCL19 and CCL21 in the control of allergic rhinitis.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17947663","citation_count":43,"is_preprint":false},{"pmid":"23740460","id":"PMC_23740460","title":"CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.","date":"2013","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/23740460","citation_count":42,"is_preprint":false},{"pmid":"16675330","id":"PMC_16675330","title":"Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model.","date":"2006","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16675330","citation_count":41,"is_preprint":false},{"pmid":"23649655","id":"PMC_23649655","title":"CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23649655","citation_count":40,"is_preprint":false},{"pmid":"19540558","id":"PMC_19540558","title":"Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal.","date":"2009","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19540558","citation_count":40,"is_preprint":false},{"pmid":"24990231","id":"PMC_24990231","title":"Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24990231","citation_count":40,"is_preprint":false},{"pmid":"37656776","id":"PMC_37656776","title":"CCR7 acts as both a sensor and a sink for CCL19 to coordinate collective leukocyte migration.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37656776","citation_count":39,"is_preprint":false},{"pmid":"30339734","id":"PMC_30339734","title":"Adipose tissue expression of CCL19 chemokine is positively associated with insulin resistance.","date":"2018","source":"Diabetes/metabolism research and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30339734","citation_count":38,"is_preprint":false},{"pmid":"28859865","id":"PMC_28859865","title":"Ischemic stroke damages the intestinal mucosa and induces alteration of the intestinal lymphocytes and CCL19 mRNA in rats.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/28859865","citation_count":38,"is_preprint":false},{"pmid":"16899521","id":"PMC_16899521","title":"CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/16899521","citation_count":37,"is_preprint":false},{"pmid":"25636509","id":"PMC_25636509","title":"Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25636509","citation_count":36,"is_preprint":false},{"pmid":"26097021","id":"PMC_26097021","title":"Protection from diet-induced obesity and insulin resistance in mice lacking CCL19-CCR7 signaling.","date":"2015","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26097021","citation_count":35,"is_preprint":false},{"pmid":"31526758","id":"PMC_31526758","title":"Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31526758","citation_count":35,"is_preprint":false},{"pmid":"21092185","id":"PMC_21092185","title":"Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21092185","citation_count":35,"is_preprint":false},{"pmid":"16047341","id":"PMC_16047341","title":"Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16047341","citation_count":34,"is_preprint":false},{"pmid":"37201522","id":"PMC_37201522","title":"CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.","date":"2023","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37201522","citation_count":33,"is_preprint":false},{"pmid":"29088748","id":"PMC_29088748","title":"Increased CCL19 expression is associated with progression in cervical cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088748","citation_count":33,"is_preprint":false},{"pmid":"26115234","id":"PMC_26115234","title":"Solution Structure of CCL19 and Identification of Overlapping CCR7 and PSGL-1 Binding Sites.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26115234","citation_count":33,"is_preprint":false},{"pmid":"31494219","id":"PMC_31494219","title":"The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus).","date":"2019","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31494219","citation_count":33,"is_preprint":false},{"pmid":"20865789","id":"PMC_20865789","title":"Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20865789","citation_count":33,"is_preprint":false},{"pmid":"12071677","id":"PMC_12071677","title":"Migration of Salmonella typhimurium --harboring bone marrow--derived dendritic cells towards the chemokines CCL19 and CCL21.","date":"2002","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12071677","citation_count":33,"is_preprint":false},{"pmid":"26504105","id":"PMC_26504105","title":"Differential ligand-signaling network of CCL19/CCL21-CCR7 system.","date":"2015","source":"Database : the journal of biological databases and curation","url":"https://pubmed.ncbi.nlm.nih.gov/26504105","citation_count":32,"is_preprint":false},{"pmid":"24915301","id":"PMC_24915301","title":"Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24915301","citation_count":32,"is_preprint":false},{"pmid":"19664149","id":"PMC_19664149","title":"Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication.","date":"2009","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19664149","citation_count":32,"is_preprint":false},{"pmid":"12626344","id":"PMC_12626344","title":"Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis.","date":"2003","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12626344","citation_count":32,"is_preprint":false},{"pmid":"15231820","id":"PMC_15231820","title":"Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3beta antagonist.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15231820","citation_count":30,"is_preprint":false},{"pmid":"27459960","id":"PMC_27459960","title":"HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.","date":"2016","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/27459960","citation_count":30,"is_preprint":false},{"pmid":"32564199","id":"PMC_32564199","title":"CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32564199","citation_count":29,"is_preprint":false},{"pmid":"32675195","id":"PMC_32675195","title":"Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32675195","citation_count":29,"is_preprint":false},{"pmid":"28619138","id":"PMC_28619138","title":"Newcastle disease virus-like particles induce DC maturation through TLR4/NF-κB pathway and facilitate DC migration by CCR7-CCL19/CCL21 axis.","date":"2017","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28619138","citation_count":29,"is_preprint":false},{"pmid":"17384577","id":"PMC_17384577","title":"CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.","date":"2007","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17384577","citation_count":29,"is_preprint":false},{"pmid":"16423060","id":"PMC_16423060","title":"Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration.","date":"2006","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16423060","citation_count":29,"is_preprint":false},{"pmid":"16500130","id":"PMC_16500130","title":"Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3beta) after exposure to Helicobacter pylori.","date":"2006","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/16500130","citation_count":28,"is_preprint":false},{"pmid":"38191529","id":"PMC_38191529","title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38191529","citation_count":28,"is_preprint":false},{"pmid":"23099886","id":"PMC_23099886","title":"CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.","date":"2012","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23099886","citation_count":28,"is_preprint":false},{"pmid":"28807994","id":"PMC_28807994","title":"A Novel Computational Model Predicts Key Regulators of Chemokine Gradient Formation in Lymph Nodes and Site-Specific Roles for CCL19 and ACKR4.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28807994","citation_count":27,"is_preprint":false},{"pmid":"34218330","id":"PMC_34218330","title":"CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance.","date":"2021","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/34218330","citation_count":27,"is_preprint":false},{"pmid":"31068931","id":"PMC_31068931","title":"Elevated CCL19/CCR7 Expression During the Disease Process of Primary Sjögren's Syndrome.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31068931","citation_count":27,"is_preprint":false},{"pmid":"28062181","id":"PMC_28062181","title":"Epicatechin downregulates adipose tissue CCL19 expression and thereby ameliorates diet-induced obesity and insulin resistance.","date":"2016","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/28062181","citation_count":27,"is_preprint":false},{"pmid":"25473269","id":"PMC_25473269","title":"CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions.","date":"2014","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25473269","citation_count":27,"is_preprint":false},{"pmid":"37956733","id":"PMC_37956733","title":"Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37956733","citation_count":26,"is_preprint":false},{"pmid":"22334704","id":"PMC_22334704","title":"CCR7/CCL19 controls expression of EDG-1 in T cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22334704","citation_count":26,"is_preprint":false},{"pmid":"28856757","id":"PMC_28856757","title":"CCL19/CCR7 contributes to the pathogenesis of endometriosis via PI3K/Akt pathway by regulating the proliferation and invasion of ESCs.","date":"2017","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/28856757","citation_count":26,"is_preprint":false},{"pmid":"29061765","id":"PMC_29061765","title":"CK12a, a CCL19-like Chemokine That Orchestrates both Nasal and Systemic Antiviral Immune Responses in Rainbow Trout.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29061765","citation_count":26,"is_preprint":false},{"pmid":"30518137","id":"PMC_30518137","title":"Fluorescently Tagged CCL19 and CCL21 to Monitor CCR7 and ACKR4 Functions.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30518137","citation_count":25,"is_preprint":false},{"pmid":"27031839","id":"PMC_27031839","title":"Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27031839","citation_count":25,"is_preprint":false},{"pmid":"16973962","id":"PMC_16973962","title":"Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16973962","citation_count":25,"is_preprint":false},{"pmid":"19171354","id":"PMC_19171354","title":"CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis.","date":"2009","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19171354","citation_count":25,"is_preprint":false},{"pmid":"24228233","id":"PMC_24228233","title":"IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients.","date":"2013","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/24228233","citation_count":25,"is_preprint":false},{"pmid":"25086360","id":"PMC_25086360","title":"Matrix metalloproteinase-9 is up-regulated by CCL19/CCR7 interaction via PI3K/Akt pathway and is involved in CCL19-driven BMSCs migration.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25086360","citation_count":25,"is_preprint":false},{"pmid":"32603491","id":"PMC_32603491","title":"MiR-325-3p inhibits renal inflammation and fibrosis by targeting CCL19 in diabetic nephropathy.","date":"2020","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32603491","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51598,"output_tokens":7507,"usd":0.133699},"stage2":{"model":"claude-opus-4-6","input_tokens":11297,"output_tokens":3461,"usd":0.214515},"total_usd":0.348214,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL19 (ELC) and CCL21 (SLC) are co-expressed by T zone stromal cells in secondary lymphoid organs; deletion of both ELC and SLC genes occurs in plt/plt mice, which show disrupted T cell and dendritic cell trafficking to lymphoid tissues.\",\n      \"method\": \"Bone marrow reconstitution, double in situ hybridization, genetic mouse model (plt/plt)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ISH, bone marrow reconstitution, genetic model) in a highly cited foundational paper\",\n      \"pmids\": [\"11070085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL19 is transcytosed from perivascular spaces to the luminal surface of high endothelial venules (HEVs), enabling CCR7-mediated T cell arrest and lymph node homing.\",\n      \"method\": \"In situ hybridization, immunostaining, footpad injection of CCL19 in mice, T cell trafficking assay in plt/plt mice\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ISH, IHC, in vivo rescue in plt/plt mice) demonstrating transcytosis and functional T cell homing\",\n      \"pmids\": [\"11342595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MRP1-mediated transport of leukotriene C4 (LTC4) is required for optimal dendritic cell chemotaxis toward CCL19; cysteinyl leukotrienes promote CCL19-dependent DC migration from the epidermis to lymph nodes.\",\n      \"method\": \"MRP1 knockout mice, exogenous LTC4/LTD4 rescue, in vitro chemotaxis assay, in vivo CCL19 antagonism\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO with rescue, in vitro and in vivo mechanistic dissection in a highly cited Cell paper\",\n      \"pmids\": [\"11114332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL19 induces rapid, concentration-dependent internalization of its receptor CCR7 and receptor desensitization, whereas CCL21 does not internalize CCR7; internalized CCR7 is re-expressed after CCL19 removal.\",\n      \"method\": \"Flow cytometry, receptor internalization assays, functional re-stimulation assays in T lymphocytes and CCR7-bearing cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays (flow cytometry, desensitization, re-expression) with clear mechanistic conclusion, widely cited\",\n      \"pmids\": [\"11745346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCR7 internalization following CCL19 (but not CCL21) binding requires arrestin 3 (beta-arrestin 2); siRNA knockdown of arrestin 3 abolishes CCL19-induced CCR7 internalization and blocks migration to CCL19 but not CCL21.\",\n      \"method\": \"siRNA knockdown of arrestin 2/3 in HuT 78 cells, arrestin 2−/−/arrestin 3−/− MEF reconstitution with GFP-tagged arrestins, immunofluorescence microscopy, migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — siRNA KD plus double-KO reconstitution with mutagenesis-equivalent rescue, multiple orthogonal methods\",\n      \"pmids\": [\"18802075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL19 (ELC) binds with high affinity to a novel atypical receptor, CCX-CKR (provisionally CCR10), in addition to CCR7; this receptor also binds CCL21 and CCL25 (TECK) but not most other chemokines.\",\n      \"method\": \"Stalkokine adhesion assay, radiolabeled ligand binding, competition with >80 chemokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct radioligand binding and competition assay with broad chemokine panel identifying CCL19 as high-affinity CCX-CKR ligand\",\n      \"pmids\": [\"10706668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCX-CKR (ACKR4) mediates efficient scavenging of CCL19 by internalizing and degrading it; unlike CCR7, CCX-CKR does not become refractory and progressively degrades large quantities of CCL19. CCX-CKR internalization is independent of beta-arrestins and clathrin-coated pits but is blocked by caveolin-1 overexpression.\",\n      \"method\": \"Transfected HEK293 cells, CCL19 internalization and degradation assays, siRNA, caveolin-1 overexpression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic assays (internalization, degradation, pathway inhibitors) in reconstituted cell system\",\n      \"pmids\": [\"16791897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCL19/CCL21-triggered migration of dendritic cells requires prostaglandin E2 (PGE2); PGE2 enables CCR7 coupling to PI3K-mediated phosphorylation of Akt and intracellular calcium mobilization. DC migration to CCL19/CCL21 depends on phospholipase C and calcium flux but not on PI3K.\",\n      \"method\": \"Human monocyte-derived DC cultures, PI3K inhibitors, calcium mobilization assays, migration assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathway dissection with pharmacological inhibitors and functional migration readouts\",\n      \"pmids\": [\"14592837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL19 solution structure contains a canonical chemokine fold; the N-termini of PSGL-1 and CCR7 have overlapping, competitively binding sites on CCL19, suggesting a mechanism by which PSGL-1 co-receptor expression enhances CCL19-driven T cell recruitment.\",\n      \"method\": \"NMR solution structure determination, chemical shift mapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with chemical shift mapping providing direct structural evidence for receptor binding sites\",\n      \"pmids\": [\"26115234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL19 is a specific ligand for the atypical receptor CRAM (CCRL2/CRAM-B); CRAM binds CCL19 with affinity similar to CCR7 but does not trigger calcium mobilization or chemotaxis; instead CRAM constitutively recycles via clathrin-coated pits and internalizes CCL19.\",\n      \"method\": \"Radioactive ligand binding, calcium mobilization assay, migration assay, constitutive recycling assay, anti-CRAM antibody internalization\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct radioligand binding and functional assays in single lab identifying CRAM as atypical CCL19 receptor\",\n      \"pmids\": [\"20002784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ACKR4 on keratinocytes and dermal lymphatic endothelial cells scavenges dermal CCL19 during cutaneous inflammation; loss of ACKR4 impairs Langerhans cell egress and dermal DC accumulation in lymph nodes, and this defect is fully rescued by genetic deletion of CCL19.\",\n      \"method\": \"Ackr4-deficient mice, Ccl19/Ackr4 double-deficient mice, flow cytometry of skin and draining LN APCs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double-KO rescue definitively placing ACKR4 upstream of CCL19 in APC egress pathway\",\n      \"pmids\": [\"26976955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL21 alone is sufficient for DC migration from skin, DC maturation, and efficient T cell priming in vivo; CCL19-deficient mice with intact CCL21 expression show normal DC homeostasis and function, demonstrating CCL19 is redundant for these processes.\",\n      \"method\": \"CCL19-deficient mice with varying CCL21 levels, flow cytometry of DC localization and frequency, T cell priming assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with functional immune readouts demonstrating dispensability of CCL19 for DC migration in vivo\",\n      \"pmids\": [\"20201039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In a 3D microfluidic system, DCs can sense CCR7 ligand gradients as small as 0.4%; CCL19 and CCL21 show similar sensitivity at small gradients but CCL21 is a more potent directional cue at higher gradients, even when matrix-binding of CCL21 is prevented, suggesting differential receptor signaling rather than matrix binding underlies the difference.\",\n      \"method\": \"Microfluidic 3D gradient device, DC chemotaxis assay in collagen matrices, neutralization of matrix binding\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative reconstituted 3D system with controlled gradients, multiple conditions tested\",\n      \"pmids\": [\"21422278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL19 (and CCL21) treatment of resting CD4+ T cells increases HIV-1 permissiveness without inducing T cell activation or proliferation, resulting in high levels of integrated HIV-1 DNA and post-integration latency upon restimulation.\",\n      \"method\": \"HIV-1 infection of purified resting CD4+ T cells pre-treated with CCL19/CCL21, integrated HIV DNA quantification, reactivation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic in vitro experiment with integration quantification and latency reactivation, highly cited\",\n      \"pmids\": [\"17881634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HIV integration in CCL19-treated resting CD4+ T cells requires NF-κB signaling; CCL19 induces phosphorylation of Akt, NF-κB, ERK, and p38, and CCL19 treatment stabilizes HIV integrase by promoting its interaction with Pin1 (reduced by JNK inhibition). HIV mutants lacking NF-κB binding sites in the LTR show 40-fold reduced integration in CCL19-treated cells versus only 5-fold reduction in activated T cells.\",\n      \"method\": \"Pathway inhibitors (PI3K, MEK, JNK, AP-1, NF-κB inhibitors), NF-κB-mutant HIV infection, Alu-LTR and 2-LTR qPCR, co-immunoprecipitation of integrase with Pin1, integration site analysis\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple pharmacological pathway dissection, mutant virus, and molecular co-IP defining NF-κB requirement\",\n      \"pmids\": [\"27459960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCR7/CCL19 signaling in T cells upregulates ERK5 expression and phosphorylation, leading to subsequent induction of KLF-2 and EDG-1 (S1P1), thereby linking CCL19-mediated lymph node entry to S1P1-dependent lymph node egress.\",\n      \"method\": \"CCL19 stimulation of HuT78 and primary murine T cells, Western blot for ERK5/KLF-2/EDG-1, ERK5 conditional KO (ERK5flox/flox/Lck-Cre), migration assay to S1P\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic KO with migration readout plus time-course signaling pathway analysis\",\n      \"pmids\": [\"22334704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCR7 functions both as a sensor (directional receptor) and as a sink (ligand consumer) for CCL19 in dendritic cells; CCR7 internalization after CCL19 binding creates a local chemokine gradient, enabling self-organized collective DC migration and long-range guidance.\",\n      \"method\": \"Live-cell imaging of DC chemotaxis, computational modeling, receptor internalization quantification, gradient visualization\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — experimental data combined with theory, multiple orthogonal methods demonstrating dual sensory/sink role\",\n      \"pmids\": [\"37656776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A CCL19 N-terminal truncation mutant CCL19(8-83) specifically antagonizes CCL19-induced chemotaxis and calcium mobilization without affecting CCL21 responses; treatment of mice with this antagonist inhibits cytotoxic T lymphocyte generation against allogeneic dendritic cells, demonstrating a specific role for CCL19 in immune priming.\",\n      \"method\": \"In vitro chemotaxis and calcium mobilization assays, in vivo CCL19 antagonist treatment, allogeneic CTL generation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — specific antagonist mutagenesis with in vitro and in vivo functional validation\",\n      \"pmids\": [\"15231820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL19/CCL21 promote activation-induced cell death (AICD) of antigen-responding CD4+ T cells during the clonal contraction phase, partially through enhancing Fas ligand expression; plt/plt mice lacking CCL19/CCL21 show prolonged T cell expansion and impaired AICD.\",\n      \"method\": \"OVA/CFA immunization of plt/plt and wild-type mice, in vivo tracking of OVA-responding T cells, in vitro AICD assay with anti-CD3/CD28, Fas ligand expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model combined with in vitro mechanistic assays and Fas ligand pathway identification\",\n      \"pmids\": [\"16973962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL19/CCR7 signaling in A549 lung cancer cells upregulates heparanase expression via transcription factor Sp1; Sp1 binds to the heparanase gene promoter (ChIP assay), and this pathway promotes tumor cell invasion.\",\n      \"method\": \"Recombinant CCL19 stimulation, CCR7 blockade, Sp1 siRNA, chromatin immunoprecipitation (ChIP), qPCR/Western blot, Transwell invasion assay\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP validation of Sp1-heparanase promoter binding plus functional invasion assay, single lab\",\n      \"pmids\": [\"23649655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PGE2 induces CCR7 expression on human monocytes and enables migration to CCL19 and CCL21 via EP2/EP4 receptor engagement, cAMP elevation, and the cAMP/PKA pathway; p38 MAPK is required for CCR7 mRNA transcription; transcription factors CREB-1, C/EBPα, and C/EBPβ translocate to the nucleus and bind the CCR7 promoter following PGE2 stimulation.\",\n      \"method\": \"PGE2 stimulation of human monocytes, cAMP measurement, PKA/p38/MAPK pathway inhibitors, transcription factor nuclear translocation and promoter binding assays, migration assay\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathway inhibitors with transcription factor binding assays, single lab\",\n      \"pmids\": [\"19545899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PGE2-matured DCs have high surface CCR7 but suppressed CCL19 production; this suppression reduces their ability to attract naive T cells. TLR ligand/IFN-matured DCs produce high CCL19 but have lower surface CCR7 due to auto-internalization in the CCL19-rich maturation environment.\",\n      \"method\": \"DC maturation protocols, CCL19 ELISA, CCR7 surface staining, in vitro migration assay for naive T cells, in vivo DC tracking with 111In-labeled DCs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo (patient) data with multiple orthogonal methods revealing CCL19 autocrine regulation of CCR7 surface expression\",\n      \"pmids\": [\"20498301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CCL19 inhibits colorectal cancer angiogenesis through a CCR7-dependent mechanism involving upregulation of miR-206, which suppresses the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway.\",\n      \"method\": \"Stable CCL19 overexpression/shRNA lentiviral transduction, HUVEC CCR7 shRNA knockdown, HUVEC proliferation/migration/sprouting assays, in vivo angiogenesis mouse model, pathway Western blot\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with CCR7 shRNA and in vivo model, pathway mechanistically defined, single lab\",\n      \"pmids\": [\"30250188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL19/CCR7 signaling in ovarian cancer cells promotes epithelial-to-mesenchymal transition (EMT) via ERK signaling, mediated through the adapter protein CrkL; CrkL knockdown suppresses CCL19-stimulated p-ERK and EMT markers (N-cadherin, Snail, MMP9) and reduces invasion, without affecting p-AKT.\",\n      \"method\": \"CrkL siRNA knockdown in SKOV-3 cells, Western blot for signaling molecules and EMT markers, Transwell invasion and wound healing assays\",\n      \"journal\": \"Medical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with pathway-specific rescue readouts, single lab\",\n      \"pmids\": [\"25636509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL19/CCR7 interaction in endometrial stromal cells activates PI3K/Akt signaling and upregulates Bcl2, MMP2, and MMP9, thereby promoting ESC proliferation and invasion contributing to endometriosis pathogenesis.\",\n      \"method\": \"ELISA of peritoneal fluid, cell proliferation and Transwell invasion assays, Western blot for p-AKT/Bcl2/MMP2/MMP9\",\n      \"journal\": \"American journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab with functional assays and pathway Western blot, moderate mechanistic depth\",\n      \"pmids\": [\"28856757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL19/CCR7 interaction in bone marrow stromal cells (BMSCs) upregulates MMP9 via PI3K/Akt pathway, promoting BMSC migration; LY294002 (PI3K inhibitor) abolishes CCL19-induced Akt phosphorylation and MMP9 upregulation.\",\n      \"method\": \"Transwell migration assay, Western blot, real-time PCR, LY294002 pharmacological inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibition with functional migration readout, single lab\",\n      \"pmids\": [\"25086360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Seminal fluid induces expression of CCL19 in uterine glandular and luminal epithelial cells, and CCL19 acts through CCR7 to recruit FOXP3+ regulatory T cells to the uterus prior to embryo implantation; both seminal plasma and sperm are required for maximal CCL19 expression.\",\n      \"method\": \"Flow cytometry, immunohistochemistry, qPCR, mating with seminal vesicle-deficient males\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (seminal vesicle KO) with multiple readouts establishing CCL19 as mediator of uterine Treg recruitment\",\n      \"pmids\": [\"21389340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCL19-expressing astrocytes are required for gliosis-induced CNS lymphoma development; CCL19 from astrocytes retains CCR7+ lymphoma cells in brain parenchyma, and deletion of CCL19 in mice or CCR7 from lymphoma cells abrogates CNS lymphoma formation.\",\n      \"method\": \"CCL19-deleted mice, CCR7-deleted lymphoma cells, two-photon microscopy, xenograft models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion of both ligand and receptor with in vivo two-photon imaging, multiple orthogonal approaches\",\n      \"pmids\": [\"31526758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CCL19-secreting fibroblasts facilitate lymphocyte trafficking to tertiary lymphoid structures (TLSs) in colorectal cancer liver metastasis; CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice.\",\n      \"method\": \"Single-cell RNA-seq, spatial transcriptomics (Stereo-seq), in vitro monoclonal antibody generation from TLS plasma cells, in vivo CCL19 treatment in humanized mouse model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiomics plus in vivo functional experiments demonstrating CCL19+ fibroblast role in TLS formation\",\n      \"pmids\": [\"39137726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Neutrophils produce biologically active CCL20 and CCL19 (MIP-3β) upon LPS or TNF-α stimulation; neutrophil supernatants induce chemotaxis of immature and mature DCs and trigger CCR7-expressing lymphocyte adhesion to ICAM-1, effects abolished by anti-CCL19 neutralizing antibodies.\",\n      \"method\": \"LPS/TNF-α stimulation of neutrophils, chemotaxis assay, integrin-dependent adhesion assay, neutralizing antibodies\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional neutralization confirms CCL19 bioactivity in neutrophil supernatants, single lab\",\n      \"pmids\": [\"11449350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL19 (ELC) is a high-affinity ligand for CCR7 on lymphocytes; CCL19 induces calcium mobilization and chemotaxis of CD4+, CD8+ T cells, and B cells but not NK cells, monocytes, or neutrophils; CCR7 mRNA is dramatically upregulated in T cells upon IL-2 or PHA+IL-2 stimulation; CCL19 and CCR7 co-localize in parafollicular regions of lymph nodes by ISH.\",\n      \"method\": \"ELC-SEAP fusion protein binding assay, calcium mobilization, chemotaxis assay, RT-PCR, in situ hybridization\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ligand binding, calcium flux, chemotaxis, and ISH establishing CCL19-CCR7 axis in lymphocyte trafficking; foundational study\",\n      \"pmids\": [\"9701028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCL19 promotes TH2 cell differentiation in allergic airway disease; recombinant CCL19 increases STAT5 phosphorylation and upregulates TH2- and IL-2-associated genes in naive CD4+ T cells; Ccl19-deficient mice show reduced allergic inflammation, less IL-4/IL-13 production, and attenuated airway hyperresponsiveness.\",\n      \"method\": \"Ccl19-deficient mice in OVA asthma model, co-culture of naive CD4+ T cells with Ccl19-deficient DCs or FRCs, recombinant CCL19 stimulation, STAT5 phosphorylation by flow cytometry, RNA-seq\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple in vitro and in vivo readouts plus signaling pathway identification\",\n      \"pmids\": [\"37956733\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL19 is a homeostatic CC chemokine that signals exclusively through CCR7 (and is scavenged by atypical receptors ACKR4/CCX-CKR and CRAM/CCRL2) to drive directed migration of T cells, dendritic cells, and other CCR7+ leukocytes into secondary lymphoid organs; upon CCR7 binding, CCL19 activates Gαi-coupled signaling (calcium flux, PI3K/Akt, ERK, NF-κB) and uniquely triggers arrestin 3-dependent CCR7 internalization and desensitization—unlike CCL21—thereby enabling DCs to act as both sensors and sinks to self-generate chemotactic gradients for collective migration; downstream CCR7/CCL19 signaling also induces ERK5→KLF-2→EDG-1 expression to couple lymph node entry with subsequent egress, promotes T cell AICD via Fas ligand upregulation, facilitates HIV integration in resting CD4+ T cells via NF-κB, drives TH2 differentiation through STAT5 phosphorylation, and in tumor contexts promotes or restrains cancer progression through modulation of immune cell trafficking, tertiary lymphoid structure formation, and angiogenesis suppression via the miR-206/Met/VEGF-A axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL19 is a homeostatic CC chemokine that directs lymphocyte and dendritic cell trafficking to secondary lymphoid organs by signaling through its primary receptor CCR7. CCL19 binds CCR7 to induce calcium mobilization, PI3K/Akt, ERK, and NF-κB signaling, and uniquely triggers arrestin 3-dependent CCR7 internalization and desensitization—unlike its co-ligand CCL21—enabling DCs to act as both gradient sensors and chemokine sinks for self-organized collective migration [PMID:9701028, PMID:18802075, PMID:37656776]. Atypical receptors ACKR4 and CCRL2 scavenge CCL19 without canonical signaling, shaping tissue chemokine gradients critical for dendritic cell egress and immune homeostasis [PMID:16791897, PMID:26976955]. Beyond lymphoid trafficking, CCL19/CCR7 signaling couples lymph node entry to S1P1-dependent egress via ERK5/KLF-2, promotes T cell activation-induced cell death through Fas ligand upregulation, drives TH2 differentiation via STAT5 phosphorylation, facilitates HIV-1 integration in resting CD4+ T cells through NF-κB, and orchestrates tertiary lymphoid structure formation in tumors [PMID:22334704, PMID:16973962, PMID:37956733, PMID:27459960, PMID:39137726].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of CCL19 as a high-affinity CCR7 ligand that selectively chemoattracts T and B cells established the molecular basis of lymphocyte guidance to lymph node parafollicular zones.\",\n      \"evidence\": \"Ligand binding assay, calcium mobilization, chemotaxis, ISH in human lymphoid tissues\",\n      \"pmids\": [\"9701028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCL19 vs CCL21 functional divergence at CCR7 not yet dissected\", \"in vivo requirement for CCL19 in lymph node homing not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Co-deletion of CCL19 and CCL21 in plt/plt mice disrupted T cell and DC trafficking to lymphoid organs, proving that CCR7 ligands are non-redundant with other chemokines for lymphoid organogenesis, while identification of CCX-CKR (ACKR4) as a second CCL19-binding receptor revealed a scavenging axis distinct from CCR7.\",\n      \"evidence\": \"plt/plt genetic model with bone marrow reconstitution and ISH; radioligand binding and competition panel for CCX-CKR\",\n      \"pmids\": [\"11070085\", \"10706668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of CCL19 vs CCL21 unresolved in plt/plt model\", \"ACKR4 scavenging mechanism and biological role in vivo unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstration that CCL19 is transcytosed across HEVs to mediate T cell arrest, and that CCL19 uniquely induces CCR7 internalization and desensitization unlike CCL21, revealed two mechanisms—luminal presentation and biased receptor regulation—by which CCL19 controls lymphocyte entry.\",\n      \"evidence\": \"Footpad injection with plt/plt rescue; flow cytometry internalization and re-expression assays in T cells\",\n      \"pmids\": [\"11342595\", \"11745346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of differential CCR7 internalization by CCL19 vs CCL21 unknown\", \"transcytosis receptor/pathway not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping of CCL19-triggered DC signaling to PGE2-dependent PI3K/Akt activation and calcium flux defined the intracellular requirements for chemotaxis, with PLC and calcium being essential while PI3K was dispensable for migration per se.\",\n      \"evidence\": \"Pharmacological pathway dissection in human monocyte-derived DCs with migration and calcium readouts\",\n      \"pmids\": [\"14592837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of parallel signaling arms to directional sensing vs speed not resolved\", \"role of Rho GTPases not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Three discoveries converged to define CCL19's broader biological actions beyond migration: ACKR4 was shown to constitutively scavenge and degrade CCL19 via a beta-arrestin-independent caveolar pathway; CCL19/CCL21 were found to promote T cell AICD via Fas ligand upregulation; and an N-terminal truncation antagonist (CCL19(8-83)) specifically blocked CCL19 signaling in vivo, enabling dissection of CCL19 vs CCL21 roles in immune priming.\",\n      \"evidence\": \"HEK293 internalization/degradation assays with siRNA; plt/plt OVA immunization with AICD readout; specific antagonist in allogeneic CTL assay\",\n      \"pmids\": [\"16791897\", \"16973962\", \"15231820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo gradient-shaping role of ACKR4 scavenging not demonstrated\", \"AICD mechanism beyond Fas ligand not explored\", \"antagonist selectivity in complex immune responses not fully tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Arrestin 3 was identified as the specific mediator of CCL19-induced CCR7 internalization and migration, resolving why CCL19 and CCL21 produce divergent receptor fates despite sharing CCR7.\",\n      \"evidence\": \"siRNA knockdown and arrestin double-KO MEF reconstitution with GFP-tagged arrestins, migration assays\",\n      \"pmids\": [\"18802075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling events from arrestin 3-CCR7 complexes not characterized\", \"phosphorylation code on CCR7 C-terminus not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"CCL19-deficient mice with intact CCL21 showed normal DC migration and T cell priming, establishing that CCL19 is dispensable for constitutive DC homeostasis and revealing functional redundancy within the CCR7 ligand pair for steady-state trafficking.\",\n      \"evidence\": \"CCL19-KO mice with flow cytometry of DC localization and T cell priming assays\",\n      \"pmids\": [\"20201039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-redundant roles of CCL19 in inflammation or specific immune contexts not yet identified\", \"whether CCL19 is required for fine-tuning gradient shape in vivo unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"CCL19/CCR7 signaling was found to activate ERK5→KLF-2→S1P1 in T cells, coupling CCL19-driven lymph node entry to subsequent S1P1-dependent egress—an unexpected feedback linking chemokine and sphingolipid receptor pathways.\",\n      \"evidence\": \"CCL19 stimulation of T cells, ERK5 conditional KO (ERK5flox/flox/Lck-Cre), S1P migration assay\",\n      \"pmids\": [\"22334704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCL21 induces the same ERK5-KLF2-S1P1 cascade not tested\", \"in vivo egress kinetics in CCL19-only vs CCL21-only settings unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"NMR solution structure of CCL19 revealed overlapping binding sites for CCR7 and PSGL-1 N-termini, providing a structural basis for co-receptor enhancement of CCL19-driven T cell recruitment.\",\n      \"evidence\": \"NMR structure determination with chemical shift perturbation mapping\",\n      \"pmids\": [\"26115234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ternary complex structure of CCL19-CCR7-PSGL-1 available\", \"functional validation of competitive binding in cell-based assays not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic epistasis showed ACKR4 scavenging of CCL19 in skin is required for DC egress to lymph nodes—Ackr4 loss impairs Langerhans cell migration, fully rescued by CCL19 deletion—while CCL19 was shown to facilitate HIV-1 integration in resting CD4+ T cells through NF-κB-dependent integrase stabilization.\",\n      \"evidence\": \"Ackr4/Ccl19 double-KO mice with DC tracking; NF-κB-mutant HIV, pathway inhibitors, co-IP of integrase with Pin1\",\n      \"pmids\": [\"26976955\", \"27459960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ACKR4-CCL19 axis operates similarly in mucosal tissues unknown\", \"HIV integration mechanism confirmed only in vitro\", \"Pin1-integrase interaction specificity to CCL19 context not verified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CCL19 produced by reactive astrocytes was shown to retain CCR7+ lymphoma cells in brain parenchyma, establishing a non-immune stromal source of CCL19 as critical for CNS lymphoma pathogenesis.\",\n      \"evidence\": \"CCL19-deleted mice and CCR7-deleted lymphoma cells with two-photon microscopy and xenograft models\",\n      \"pmids\": [\"31526758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism applies to other brain-tropic malignancies unknown\", \"astrocyte signals inducing CCL19 not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Two parallel advances redefined CCL19's roles: CCR7 was shown to function as both sensor and sink for CCL19, with ligand consumption enabling self-generated gradients for collective DC migration; separately, CCL19 was found to promote TH2 differentiation via STAT5 phosphorylation, with Ccl19-KO mice showing attenuated allergic airway disease.\",\n      \"evidence\": \"Live-cell DC imaging with computational modeling; Ccl19-KO in OVA asthma model with STAT5 flow cytometry and RNA-seq\",\n      \"pmids\": [\"37656776\", \"37956733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical basis of CCR7 ligand consumption kinetics not resolved at structural level\", \"whether STAT5 activation is direct or mediated via IL-2 autocrine loop unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CCL19-secreting fibroblasts were identified as organizers of tertiary lymphoid structures in colorectal cancer liver metastasis, with exogenous CCL19 promoting TLS neogenesis and anti-tumor immunity in vivo.\",\n      \"evidence\": \"Single-cell RNA-seq, spatial transcriptomics, humanized mouse model with CCL19 treatment\",\n      \"pmids\": [\"39137726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signals initiating CCL19 expression in tumor fibroblasts not defined\", \"whether CCL19 alone is sufficient or acts with CCL21 for TLS maturation unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of differential arrestin recruitment by CCL19 vs CCL21 at CCR7, the phosphorylation barcode on CCR7 that distinguishes the two ligands, whether CCL19's STAT5-mediated TH2-polarizing function operates independently of its chemotactic role, and how CCL19 production is transcriptionally regulated in non-immune stromal cells such as astrocytes and fibroblasts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No CCR7 phosphosite-resolved structure with CCL19 vs CCL21\", \"STAT5 activation mechanism (direct vs indirect) unresolved\", \"transcriptional regulation of CCL19 in stromal cells poorly characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [30, 3, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [30, 7, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 28, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 11, 17, 18, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 14, 15, 22, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 14, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR7\",\n      \"ACKR4\",\n      \"CCRL2\",\n      \"ARRB2\",\n      \"PSGL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}